NeuroTech Newsletter #15
Executive Summary
Welcome to the 15th edition of the Carter Sciences Neurotech Newsletter!
As neurotechnology surges forward, this edition captures a vibrant wave of innovation: robust funding rounds fueling AI-driven diagnostics and remote monitoring for Parkinson's and epilepsy, alongside FDA clearances accelerating non-invasive neuromodulation for depression, pain, and paralysis treatment. Clinical breakthroughs highlight minimally invasive brain-computer interfaces and light therapies transforming Alzheimer's detection and stroke recovery, while commercial launches of wearable BCIs and strategic partnerships like Methinks-Siemens signal a shift toward accessible, consumer-friendly neurotech. Leadership appointments underscore a maturing industry poised for commercialization, promising enhanced patient outcomes and market expansion—dive in to uncover how these developments are reshaping neurological care.
Check out the highlights below and as always send through any recommendations or feedback to chay@cartersciences.com
Funding News
Kneu Health Secures $5.6M to Scale Next-Generation Neurology Care
Kneu Health | 2025-10-09
Kneu Health has raised $5.6 million to expand its smartphone-based platform for monitoring Parkinson's and dementia, leveraging one of the world's largest datasets on these conditions and gaining adoption in major U.S. health systems and NHS Trusts. The FDA-cleared app tracks motor, speech, and cognitive changes remotely, embedding proactive care into everyday life to manage neurodegenerative decline at scale.
Neuronoff Closes Oversubscribed $4.5M Round for Injectrode Launch
PR Newswire | 2025-10-08
Neuronoff, a clinical-stage medical device firm, secured an oversubscribed $4.5 million financing round to push its Injectrode platform toward FDA clearance and commercial rollout. The peripheral nerve stimulation system offers a minimally invasive, drug-free option for chronic pain treatment, with funds earmarked for scaling production to 1,000 units annually and initiating limited U.S. market entry.
Medtronic raises €1.5B in senior notes offering
MassDevice | 2025-10-06
Medtronic completed a €1.5 billion ($1.76 billion) public offering of senior notes, comprising €750 million at 2.95% due 2030 and €750 million at 4.20% due 2045, fully guaranteed by the company and its subsidiary. The net proceeds of approximately €1.49 billion will support general corporate purposes, bolstering the medtech giant's financial flexibility amid ongoing neurotechnology investments.
Eysz, Inc. Awarded NIH SBIR Grant for Epilepsy Monitoring Expansion
EIN Presswire | 2025-10-03
Eysz, a digital health firm targeting neurological and psychiatric diagnostics, received a NIH SBIR Fast-Track grant from the National Institute of Nursing Research to extend its Eysz HV Recorder app beyond clinic-based screening for childhood absence epilepsy into remote home monitoring. This funding validates the smartphone tool's potential to enhance early detection and treatment accessibility for pediatric epilepsy patients.
Natus Acquires Holberg EEG for AI Neurodiagnostics Innovation
PR Newswire | 2025-09-30
Natus Medical acquired the remaining minority stake in Holberg EEG, achieving full ownership of the developer behind the world's first AI model for automatic, expert-level EEG interpretation. This move strengthens Natus's position as a global leader in neurodiagnostics by integrating advanced AI to streamline clinical EEG analysis and improve diagnostic efficiency across neurological conditions.
UC 1819-backed startup Sense Neuro fueled by $17 million
University of Cincinnati | 2025-09-29
Sense Neuro Diagnostics, supported by UC 1819 and Cincinnati's startup ecosystem, has raised over $17 million over the past decade to advance non-invasive brain monitoring for stroke and brain injury patients. The funding underscores collaborative efforts to enhance recovery outcomes through innovative neurotechnology, highlighting regional strengths in translating research into clinical tools.
Industry Analysis
These funding rounds and acquisitions signal robust investor confidence in neurotechnology, potentially accelerating innovation in remote monitoring, AI-driven diagnostics, and minimally invasive pain management, which could lower healthcare costs and improve patient access while intensifying competition among startups and incumbents like Medtronic and Natus.
Trend Conclusion
A clear trend emerges toward digital and AI integration in neurology, with smartphone apps and automated EEG tools gaining traction for scalable, non-invasive care in neurodegenerative diseases, epilepsy, and chronic pain, driven by grants and oversubscribed investments that prioritize home-based solutions over traditional clinic models.
Regulatory & Reimbursement News
inTRAvent Medical Secures FDA Clearance for Next-Gen SOLOPASS® 2.0 Navigation System
BusinessWire | 2025-10-10
inTRAvent Medical Partners LP has obtained FDA 510(k) clearance for its SOLOPASS® 2.0 navigation system, an advanced intra-operative imaging and navigation tool designed to enhance neurosurgical procedures by delivering real-time, precise guidance directly at the patient's bedside, potentially improving surgical accuracy and outcomes in neurotechnology applications.
FDA clears accelerated protocol for BrainsWay Deep TMS in depression
BrainsWay | 2025-10-10
The FDA has expanded clearance for BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) system, approving an accelerated treatment protocol for major depressive disorder, including cases with comorbid anxiety, which shortens the acute phase to six days of sessions under 10 minutes each, compared to the standard four-week regimen, offering faster access to non-invasive neuromodulation therapy.
xStep Device Secures CDSCO Approval for Paralysis Treatment
LinkedIn | 2025-10-09
SpineX Inc.'s xStep device, a non-invasive spinal cord neuromodulation system for neurorehabilitation, has received approval from India's Central Drugs Standard Control Organization (CDSCO) for clinical and home use in treating paralysis, enabling painless electrical stimulation to restore movement and independence without surgery; previously designated as a U.S. FDA Breakthrough Device, this milestone supports global expansion in neuromodulation technologies.
LinkedIn | 2025-10-01
NeuroOne Medical Technologies Corporation has secured FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System, enabling radiofrequency lesioning to treat facial pain and support functional neurosurgical procedures targeting neurological disorders, which could expand minimally invasive options for pain management in the neurotechnology sector.
Regulatory Impact Analysis
These recent FDA clearances for navigation systems, transcranial magnetic stimulation protocols, and ablation devices underscore a surge in approvals for innovative neurotechnologies aimed at enhancing surgical precision, accelerating mental health treatments, and addressing chronic pain and mobility impairments. This momentum may accelerate market entry for companies like inTRAvent, BrainsWay, and NeuroOne, foster investment in non-invasive neuromodulation, and encourage international alignments, such as the xStep's CDSCO nod building on U.S. breakthrough status, ultimately benefiting patients through broader access to advanced therapies while pressuring competitors to innovate rapidly.
Regulatory Trend Conclusion
The articles reveal a clear trend toward expedited and expanded regulatory pathways in neurotechnology, with multiple 510(k) clearances in October 2025 emphasizing non-invasive and bedside-accessible devices for depression, pain, and neurosurgery. This pattern highlights the FDA's prioritization of patient-centric innovations like accelerated protocols and neuromodulation, signaling a maturing ecosystem that could streamline future approvals and drive convergence between U.S. and global standards to address unmet needs in neurological care.
Clinical News
Minimally invasive implantation of scalable high-density cortical microelectrode arrays
Nature Biomedical Engineering | 2025-10-10
Researchers have developed a 1,024-channel thin-film microelectrode array for high-bandwidth brain-computer interfaces, enabling minimally invasive implantation without craniotomy in porcine models and human cadavers, allowing reversible delivery to multiple cortical regions for simultaneous neural recording and stimulation across large surface areas.
LIFU Modulates ALIC Tracts in Refractory Depression
PubMed | 2025-10-10
A study explored low-intensity focused ultrasound (LIFU) to modulate white matter tracts in the anterior limb of the internal capsule, a target for refractory depression treatment, offering a non-invasive alternative to intracranial electrodes for establishing precise deep brain circuit-symptom relationships and predicting surgical outcomes.
ViewMind Atlas™ Detects Early Alzheimer’s Risk with 96% Accuracy
LinkedIn / ViewMind Inc. | 2025-10-09
A publication in Brain Communications validated ViewMind Atlas™ technology, achieving 96% sensitivity and specificity in identifying asymptomatic PSEN1 gene mutation carriers at risk for Alzheimer's up to 18 years before symptoms, leveraging digital cognitive biomarkers from eye movements to enable early detection of brain changes.
Syntropic Publishes First Study on 60Hz Light Therapy for Depression
LinkedIn / Syntropic | 2025-10-08
In a peer-reviewed PLOS One study, Syntropic demonstrated that 60 Hz light stimulation safely induces neural synchronization across visual, parietal, temporal, and frontal regions in depression patients, promoting frequency entrainment as a non-invasive, non-pharmacological therapy to alleviate symptoms through widespread brain modulation.
Yahoo Finance / Nexalin Technology | 2025-10-08
A peer-reviewed trial published in Radiology showed Nexalin's 40-Hz DIFS™ neurostimulation device significantly enhancing cognitive performance and brain connectivity in Alzheimer's patients, marking a clinical advancement in non-invasive deep intracranial frequency stimulation for neurodegenerative disorders.
ClearPoint Neuro Announces Promising Brain Tumor Laser Therapy Results
ClearPoint Neuro Investor Relations | 2025-10-07
Phase I-II clinical results from Skåne University Hospital validated the safety, feasibility, and efficacy of ClearPoint's Prism Neuro Laser Therapy System for brain tumors, enabling precise navigation and treatment to improve outcomes in neuro-oncology applications.
Closed-Loop Vagus Nerve Stimulation Miniaturized System for Chronic Stroke Recovery
American Heart Association Journals | 2025-10-07
Researchers introduced a miniaturized closed-loop vagus nerve stimulation system, building on FDA-approved task-oriented training pairings to enhance upper limb recovery in chronic stroke patients, offering improvements over legacy designs for better integration and efficacy in neuromodulation.
PR Newswire / Cala | 2025-10-06
A Brain Stimulation journal study from University of Wisconsin-Madison confirmed that Cala's non-invasive transcutaneous afferent patterned stimulation (TAPS) therapy directly modulates brain neural activity to reduce hand tremors in essential tremor patients, providing mechanistic evidence for its therapeutic mechanism.
Innovations in Neurology: The Rise of Noninvasive Devices
Medical Tech Outlook Europe | 2025-10-06
Advancements in noninvasive neurological devices are transforming diagnosis, monitoring, and treatment of disorders through neuromodulation and brain activity tracking, offering safer alternatives that enhance precision and accessibility in neurology while addressing a broad spectrum of conditions.
Ultrasound Breakthrough Targets Multiple Brain Networks at Once
Neuroscience News | 2025-10-03
A novel ultrasound device enables simultaneous stimulation of multiple precise brain points with lower-intensity pulses to minimize risks like overheating, while integrating real-time visualization of affected networks, advancing non-invasive neuromodulation for diverse neurological applications.
Fierce Biotech | 2025-10-03
Published in Nature Biomedical Engineering, a study detailed Precision Neuroscience's Layer 7 cortical interface, which collects high-bandwidth neural data and delivers stimulation via a minimally invasive micro-slit technique in five human patients, demonstrating safety and efficacy without deep tissue penetration.
SONIC: A Benchmarking Paradigm for Brain-Computer Interfaces
bioRxiv | 2025-10-02
The SONIC framework benchmarks brain-computer interfaces by evaluating information transfer capacity essential for applications like speech synthesis, using neural recordings to standardize performance assessment and accelerate development for neurological disorder restoration and human-digital interaction.
Transfer learning via distributed brain recordings enables reliable speech decoding
Nature Communications | 2025-10-01
Utilizing stereo-electroencephalography in a large cohort during speech tasks, researchers developed transfer learning strategies for speech brain-computer interfaces, enabling scalable, reliable decoding across individuals with varying brain organization by leveraging distributed recordings and large language models.
Nyxoah Achieves First Genio Commercial Implants in US
LinkedIn / Nyxoah | 2025-09-30
Nyxoah completed its first commercial Genio implants for obstructive sleep apnea in the US at Baylor College of Medicine, marking regulatory approval and clinical expansion with procedures led by experts to improve patient access to hypoglossal nerve stimulation therapy.
A neuronal architecture underlying autonomic dysreflexia
Nature | 2025-09-17
This preclinical study elucidated the neuronal mechanisms of autonomic dysreflexia post-spinal cord injury, identifying pathways that trigger hypertension episodes in response to stimuli, providing foundational insights to develop targeted therapies and mitigate risks like heart attack and stroke in affected patients.
Clinical Impact Analysis
These developments in neurotechnology, spanning minimally invasive brain-computer interfaces, non-invasive neuromodulation, and early detection tools, promise to enhance precision in treating conditions like Alzheimer's, depression, stroke, and tremors, potentially reducing surgical risks and improving accessibility to therapies, thereby transforming patient care through faster diagnosis and personalized interventions while lowering healthcare burdens in the industry.
Research Trend Conclusion
A prominent trend across these articles is the shift toward minimally invasive and non-invasive technologies, such as ultrasound, light therapy, and thin-film arrays, which prioritize safety and scalability over traditional invasive methods, alongside growing emphasis on AI-integrated biomarkers and transfer learning to enable broader clinical translation and individualized neurotherapeutics in the field.
Commercial Collaborations and Launches
Neurable Launches MW75 Neuro LT BCI Headphones
Neurable | 2025-10-10
Neurable has launched the MW75 Neuro LT, an advanced iteration of its brain-computer interface headphones that detects mental fatigue in real time, incorporating user feedback for a lighter design and improved all-day comfort while retaining robust brain-sensing technology to target consumer markets focused on productivity and wellness.
Atlas Launches Brainwave Wearable, Secures $14M Funding
LinkedIn | 2025-10-09
Atlas has unveiled a compact, behind-the-ear wearable device for real-time brainwave monitoring to optimize focus, reduce stress, and boost performance, backed by $14 million in funding that supports its nanotechnology-driven commercialization strategy aimed at everyday users and performance enhancement sectors.
Paradromics Unveils SONIC Benchmark, Hits 200+ Bits per Second
LinkedIn | 2025-10-03
Paradromics has introduced the SONIC benchmarking standard for brain-computer interfaces in a scientific preprint, demonstrating over 200 bits per second throughput with its chronic, wireless Connexus BCI more than 10 months post-implantation, advancing commercial viability for high-performance neural prosthetics in medical and research applications.
OpenBCI Launches Galea NEON Headset with Pupil Labs
LinkedIn | 2025-10-02
OpenBCI has launched the Galea NEON headset in collaboration with Pupil Labs and key developers, marking the first untethered all-in-one device for brain, body, and eye tracking that supports seamless transitions between screens, XR, and real-world interactions with synchronized data streaming to drive open-source innovation in neurotechnology accessibility.
Methinks and Siemens Healthineers partner on AI stroke solutions
NeuroNews International | 2025-10-02
Methinks and Siemens Healthineers have formed a strategic partnership to deploy AI-driven digital solutions for stroke management in southern European markets, announced at Siemens' new AI in Healthcare Centre in Madrid, aiming to accelerate digital transformation across Greece, Italy, Portugal, and beyond through integrated clinical tools.
Cognixion Launches BCI Clinical Trial with Apple Vision Pro
LinkedIn | 2025-10-01
Cognixion has initiated a clinical trial merging its noninvasive EEG-based brain-computer interface with Apple Vision Pro to empower individuals with disabilities in communication and daily independence, representing an early commercial exploration of integrated XR-neurotech systems with potential for broader assistive technology adoption.
Market Impact Analysis
These commercial developments in neurotechnology, including multiple wearable BCI launches and strategic AI partnerships, are poised to intensify market competition by lowering barriers to entry for consumer and clinical applications, prompting established players to accelerate innovation in data integration and user-centric designs while fostering industry growth through enhanced funding and regional expansions that could expand the addressable market beyond traditional medical segments into wellness and productivity.
Commercial Trend Conclusion
A clear trend emerges in the proliferation of noninvasive, wearable BCI devices emphasizing real-time monitoring and integration with existing ecosystems like XR, alongside partnerships blending neurotech with AI for targeted therapies, signaling a shift toward accessible, hybrid go-to-market strategies that prioritize user feedback, open standards, and collaborative scaling to capture emerging consumer and healthcare demands.
Leadership Appointments
Encora Therapeutics Names Nadim Yared as Chairman and CEO
| 2025-10-10
Encora Therapeutics has appointed Nadim Yared as Chairman and Chief Executive Officer, effective immediately, to lead the clinical-stage medtech company's neuromodulation therapy for movement disorders. Yared succeeds co-founder Daniel Carballo, who transitions to VP of Strategy, with the new leadership focusing on advancing late-stage clinical programs, regulatory pathways, and strategic partnerships.
Alex Stokoe Appointed Head of Product at Crainio
| 2025-10-09
Alex Stokoe has been appointed Head of Product at Crainio, where he will drive the commercialization of the company's non-invasive intracranial pressure monitoring technology for neuro trauma care. Bringing experience from TTP plc, Stokoe aims to leverage networks in London, including CMOs, NHS innovators, software developers, and quality experts, to accelerate market entry and product development.
Flow Neuroscience Appoints Hassan Chaudhury as Advisor
| 2025-10-09
Flow Neuroscience has appointed Hassan Chaudhury HonFAPM as an advisor, tapping his expertise in scaling health tech businesses, commercial partnerships, and global market access to bridge evidence with providers and stakeholders. This move supports the company's efforts to expand innovative mental health solutions internationally through effective adoption strategies.
Pratik R. Patel Appointed Head of Commercial at Sora Neuroscience
| 2025-10-07
Pratik R. Patel has joined Sora Neuroscience as Head of Commercial, returning to neurotech to advance the Cirrus resting-state platform for functional brain mapping in collaboration with Washington University in St. Louis and team leaders like Stephen Schaefer. His role emphasizes commercialization to improve patient outcomes through enhanced neuroimaging for healthcare providers.
Subsense Appoints Michael Nketiah as SVP of Regulatory & Clinical Trials
| 2025-10-06
Subsense Inc. has appointed Michael Nketiah, MBA, RAC, as Senior Vice President of Regulatory & Clinical Trials, leveraging his nearly three decades of experience in regulatory, clinical, and quality systems for medical technologies. This addition will propel the company's non-surgical, nanoparticle-based brain-computer interface toward clinical evaluation and broader adoption.
| 2025-09-30
Resonant Link Medical has appointed Raymond W. Cohen, a veteran medtech leader, as Chair of its Board of Directors to guide the expansion of the Aurion WPT™ wireless power transfer platform for implantable devices. Cohen's expertise addresses key challenges in device power requirements, fostering broader clinical applications and adoption.
iota Biosciences Appoints Carmela C. as Clinical Operations Director
| 2025-09-30
iota Biosciences, powered by Astellas, has appointed Carmela C. as Director of Clinical Operations, bringing over 20 years of experience in medical device development, including IDE studies for Class III implants from roles at University of Michigan, Terumo, Occultech, and Amber Therapeutics. Her leadership will enhance clinical strategies for the company's bioelectronic medicines.
NeuroLight Appoints Dr. Frank Nagy as Chief Clinical Officer and Director of Business Development
| 2025-09-30
NeuroLight, Inc. has appointed Dr. Frank Nagy as Chief Clinical Officer and Director of Business Development, utilizing his decade-plus experience in medical affairs and clinical development across neurology, psychiatry, and rare diseases. In this dual role, he will advance brain state transfer solutions for neurological disorders through clinical and partnership initiatives.
ClearPoint Neuro Announces Appointment of Dr. Paul Larson as Chief Medical Officer
| 2025-09-25
ClearPoint Neuro has announced the appointment of Dr. Paul Larson as Chief Medical Officer, effective January 2026, drawing on his advisory history with the company in education, product development, and cell/gene therapy delivery for brain and spine navigation. This internal promotion strengthens expertise in global device and therapy enabling technologies.
Orbit Appoints Jeff C. Jensen as Founding Engineer
| 2025-09-22
Orbit has appointed Jeff C. Jensen as Founding Engineer to develop brain-computer interfaces for decoding emotions and enhancing empathetic interactions. With prior experience as CTO at Blackrock Neurotech and VP of Engineering at Creator, Jensen's hire, sparked by industry event discussions on consciousness, bolsters the team's technical foundation.
Ruten Inc Hires Dr. Tomomichi Oya as Senior Scientist
| 2025-09-22
Ruten Inc. has hired Dr. Tomomichi Oya as Senior Scientist in Tokyo, adding his extensive background in central and peripheral nervous system research and data collection to support the company's brain-machine interface projects and ongoing innovations.
Leadership Impact Analysis
These leadership appointments across the neurotechnology sector signal a strategic push toward clinical advancement, commercialization, and regulatory expertise, potentially accelerating innovation in neuromodulation, brain-computer interfaces, and wireless implantable technologies while enhancing partnerships with academic and healthcare entities to address power, monitoring, and therapy delivery challenges, thereby influencing market dynamics through faster adoption and competitive differentiation.
Executive Trend Conclusion
A clear trend emerges in hiring seasoned experts from medtech, neurology, and regulatory fields to C-suite and senior roles, emphasizing clinical trials, business development, and global scaling, which reflects the industry's maturation as companies prioritize bridging R&D with market viability amid rising demand for non-invasive and empathetic neuro solutions.
Closing Thoughts
Key Strategic Insights
This week's neurotechnology landscape reveals a unified push toward non-invasive, AI-augmented solutions that democratize neurological care, with $5.6M for Kneu's remote Parkinson's monitoring, $4.5M for Neuronoff's pain therapy, and Natus's AI EEG acquisition underscoring investor bets on scalable digital tools over traditional hardware; regulatory wins like FDA clearances for BrainsWay's accelerated TMS and inTRAvent's bedside navigation, alongside clinical validations of ViewMind's 96% accurate Alzheimer's detection and Cala's tremor-modulating stimulation, highlight how these innovations reduce barriers to entry, enhance precision, and lower costs, while commercial launches such as Neurable's fatigue-tracking headphones and Paradromics' 200+ bps BCI benchmark signal a blurring of medical and consumer boundaries; leadership hires like Nadim Yared at Encora and Michael Nketiah at Subsense further fortify commercialization pipelines, collectively driving a narrative of efficiency gains that could compress development timelines by 20-30% and expand addressable markets to include wellness sectors, compelling executives to prioritize agile supply chains and IP protection amid intensifying competition.
Cross-Functional Analysis
Funding inflows are catalyzing regulatory and clinical synergies, as seen in Eysz's NIH grant fueling remote epilepsy monitoring that aligns with FDA's emphasis on patient-centric devices like NeuroOne's ablation system and xStep's global neuromodulation approval, while clinical breakthroughs in minimally invasive BCIs from Precision Neuroscience and closed-loop vagus stimulation for stroke recovery provide the evidentiary backbone for commercial ventures, including Methinks-Siemens AI stroke partnerships and Cognixion's XR-BCI trials; leadership appointments, such as Pratik Patel's commercial role at Sora Neuroscience and Raymond Cohen's board chair at Resonant Link, bridge these silos by injecting regulatory expertise and market savvy, enabling seamless integration of AI biomarkers—like transfer learning for speech decoding—with wearable launches from Atlas and OpenBCI, ultimately revealing an ecosystem where non-invasive tech convergence not only accelerates therapy adoption but also mitigates reimbursement hurdles through demonstrated outcomes, positioning incumbents like Medtronic to leverage their €1.5B war chest for strategic acquisitions that outpace startup agility.
Future Outlook & Recommendations
As non-invasive neuromodulation and AI-driven diagnostics mature, expect a 2026 surge in hybrid consumer-clinical adoption, with BCI wearables like Galea NEON and Syntropic's light therapy scaling to everyday use for mental health and productivity, potentially capturing a $50B+ market segment while regulatory harmonization—evident in CDSCO's xStep nod—facilitates global rollouts; executives should prioritize cross-sector alliances, such as those blending neurotech with XR platforms, and invest in ethical AI frameworks to preempt data privacy concerns, while divesting from legacy invasive assets to fund R&D in ultrasound and 40Hz stimulation for neurodegenerative diseases; monitor NIH and FDA fast-tracks for early movers, and conduct scenario planning for reimbursement models that reward outcome-based pricing, ensuring portfolios align with the shift to preventive, home-based neurology that could halve chronic care expenditures over the next decade.
Final Word
Neurotechnology's inflection point demands bold reconfiguration: embrace the non-invasive revolution to redefine neurological health as accessible empowerment, or risk obsolescence in a wired future.
© 2025 Carter Sciences. All rights reserved.
This newsletter is compiled for professionals in the Neurotechnology industry.
